Free Trial
NASDAQ:PODD

Insulet Q1 2025 Earnings Report

Insulet logo
$257.01 +6.76 (+2.70%)
Closing price 04:00 PM Eastern
Extended Trading
$254.55 -2.46 (-0.96%)
As of 04:29 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Insulet EPS Results

Actual EPS
N/A
Consensus EPS
$0.81
Beat/Miss
N/A
One Year Ago EPS
N/A

Insulet Revenue Results

Actual Revenue
N/A
Expected Revenue
$543.20 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Insulet Announcement Details

Quarter
Q1 2025
Time
After Market Closes
Conference Call Date
Thursday, May 8, 2025
Conference Call Time
4:30PM ET

Conference Call Resources

Insulet Earnings Headlines

Insulet (NASDAQ:PODD) Stock Rating Lowered by Wolfe Research
The Man I Turn to In Times Like This
A storm is brewing in the markets: new tariffs, recession warnings, and panic in the headlines. That’s when publisher Brett Aitken turns to Whitney Tilson—a man CNBC once dubbed “The Prophet.” Tilson just released a new prediction that runs counter to what mainstream finance is telling you.
Wolfe Research Downgrades Insulet (PODD)
See More Insulet Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Insulet? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Insulet and other key companies, straight to your email.

About Insulet

Insulet (NASDAQ:PODD) develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, the Middle East, Australia, and internationally. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.

View Insulet Profile

More Earnings Resources from MarketBeat